The FDA has asked manufacturers of GLP-1 receptor agonists to remove information about the risks of suicidal behavior and suicidal ideation from the drug labels.[1] The agency announced the request on Tuesday after a detailed review of existing data.[1] A preliminary evaluation by the FDA found no evidence that use of these drugs causes suicidal thoughts or actions.[1] Reviews of clinical trials, including large outcome studies and observational studies, did not reveal an association between GLP-1 agonists and the occurrence of suicidal thoughts or actions.[1] Because of the small number of observed cases in both the GLP-1 agonist and control groups, the FDA cannot definitively rule out a small risk and continues to investigate.[1] Patients should not stop taking GLP-1 agonists without consulting a doctor, as this may worsen their condition.[1] Physicians should monitor patients for new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior.[1] GLP-1 agonists are used to treat type 2 diabetes or for weight loss in obese or overweight people.[1]